| Nov 2 |
Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds
|
| Oct 28 |
We're Keeping An Eye On Cadrenal Therapeutics' (NASDAQ:CVKD) Cash Burn Rate
|
| Oct 24 |
Cadrenal Therapeutics raises $5.1M via at-the-market facility
|
| Oct 24 |
Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility
|
| Oct 23 |
CADRENAL THERAPEUTICS JOINS CORPORATE COUNCIL OF ANTICOAGULATION FORUM
|
| Sep 23 |
Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor Conference
|
| Sep 12 |
Why Champions Oncology Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
|
| Sep 11 |
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing
|
| Aug 22 |
Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients
|
| Aug 20 |
Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients
|
